| Paris | |
| 137 | |
| ABIVAX is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the worlds most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. | |
| ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine recently approved in Cuba and in late-stage clinical development in other countries that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. | |
| EHRLICH Hartmut | |
| www.abivax.com | |
| ABVX:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 17 fois.